Valuation Update With 7 Day Price Move • 19h
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩22,750, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 386% over the past three years. New Risk • May 23
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 41% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (41% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (15% average weekly change). Valuation Update With 7 Day Price Move • May 11
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩23,250, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total returns to shareholders of 421% over the past three years. Valuation Update With 7 Day Price Move • Mar 26
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₩28,750, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 18x in the Personal Products industry in South Korea. Total returns to shareholders of 523% over the past three years. Reported Earnings • Mar 20
Full year 2025 earnings released: EPS: ₩2,414 (vs ₩1,036 in FY 2024) Full year 2025 results: EPS: ₩2,414 (up from ₩1,036 in FY 2024). Revenue: ₩78.2b (up 57% from FY 2024). Net income: ₩18.9b (up 150% from FY 2024). Profit margin: 24% (up from 15% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has only increased by 77% per year, which means it is significantly lagging earnings growth. Duyuru • Mar 10
Genic Co., Ltd., Annual General Meeting, Mar 24, 2026 Genic Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 5, saneopdanji-ro 5-gil, seongdong-myeon, chungcheongnam-do, nonsan South Korea Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to ₩16,570, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total returns to shareholders of 227% over the past three years. Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment improves as stock rises 43% After last week's 43% share price gain to ₩23,350, the stock trades at a trailing P/E ratio of 10x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 350% over the past three years. New Risk • Feb 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). High level of non-cash earnings (25% accrual ratio). Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩18,980, the stock trades at a trailing P/E ratio of 8.1x. Average trailing P/E is 19x in the Personal Products industry in South Korea. Total returns to shareholders of 280% over the past three years. Valuation Update With 7 Day Price Move • Nov 21
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₩17,900, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 282% over the past three years. New Risk • Nov 18
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩135.1b (US$92.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Market cap is less than US$100m (₩135.1b market cap, or US$92.2m). Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩23,000, the stock trades at a trailing P/E ratio of 12.1x. Average trailing P/E is 20x in the Personal Products industry in South Korea. Total returns to shareholders of 469% over the past three years. Valuation Update With 7 Day Price Move • Oct 14
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩21,200, the stock trades at a trailing P/E ratio of 11.1x. Average trailing P/E is 21x in the Personal Products industry in South Korea. Total returns to shareholders of 440% over the past three years. Buy Or Sell Opportunity • Aug 12
Now 25% undervalued Over the last 90 days, the stock has risen 20% to ₩31,250. The fair value is estimated to be ₩41,431, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Jun 13
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩41,600, the stock trades at a trailing P/E ratio of 27.8x. Average trailing P/E is 18x in the Personal Products industry in South Korea. Total returns to shareholders of 857% over the past three years. Valuation Update With 7 Day Price Move • May 26
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₩31,750, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 16x in the Personal Products industry in South Korea. Total returns to shareholders of 477% over the past three years. Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to ₩17,800, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 14x in the Personal Products industry in South Korea. Total returns to shareholders of 199% over the past three years. New Risk • Apr 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩147.1b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (42% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₩147.1b market cap, or US$99.9m). Reported Earnings • Mar 22
Full year 2024 earnings released: EPS: ₩1,036 (vs ₩643 loss in FY 2023) Full year 2024 results: EPS: ₩1,036 (up from ₩643 loss in FY 2023). Revenue: ₩49.9b (up 78% from FY 2023). Net income: ₩7.56b (up ₩12.0b from FY 2023). Profit margin: 15% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 61% per year whereas the company’s share price has increased by 60% per year. Duyuru • Mar 12
Genic Co., Ltd., Annual General Meeting, Mar 26, 2025 Genic Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 5, saneopdanji-ro 5-gil, seongdong-myeon, chungcheongnam-do, nonsan South Korea New Risk • Dec 09
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.2b free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩134.2b market cap, or US$93.5m). New Risk • Dec 07
New minor risk - Financial data availability Less than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩2.1b). Less than 3 years of financial data is available. Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩134.2b market cap, or US$94.3m). New Risk • Dec 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.2b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩2.2b free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 22% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩123.7b market cap, or US$88.1m). New Risk • Nov 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩133.3b (US$94.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩133.3b market cap, or US$94.9m). New Risk • Aug 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩42.2b market cap, or US$31.7m). New Risk • Jul 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₩26.5b market cap, or US$19.2m). New Risk • Sep 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩2.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩2.3b free cash flow). Minor Risk Market cap is less than US$100m (₩28.3b market cap, or US$21.4m). Buying Opportunity • Dec 23
Now 25% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be ₩5,922, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 73%. Buying Opportunity • Dec 06
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 3.0%. The fair value is estimated to be ₩6,492, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has declined by 73%. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • May 18
First quarter 2022 earnings released: ₩342 loss per share (vs ₩46.00 profit in 1Q 2021) First quarter 2022 results: ₩342 loss per share (down from ₩46.00 profit in 1Q 2021). Revenue: ₩7.81b (down 25% from 1Q 2021). Net loss: ₩2.35b (down ₩2.66b from profit in 1Q 2021). Over the last 3 years on average, earnings per share has increased by 45% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 1 independent director (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Is New 90 Day High Low • Mar 02
New 90-day high: ₩5,660 The company is up 53% from its price of ₩3,705 on 02 December 2020. The South Korean market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Personal Products industry, which is up 10.0% over the same period. Is New 90 Day High Low • Jan 27
New 90-day high: ₩4,700 The company is up 28% from its price of ₩3,685 on 29 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is up 18% over the same period. Is New 90 Day High Low • Jan 07
New 90-day high: ₩3,995 The company is up 2.0% from its price of ₩3,910 on 08 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 7.0% over the same period. Is New 90 Day High Low • Sep 23
New 90-day low: ₩3,720 The company is down 6.0% from its price of ₩3,975 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period.